Healthcare provider profile · identity verified

Daniel Polanco, MD

Internal Medicine · EL PASO, TX · NPI 1568469856

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	1374	431
Metformin Hcl	Metformin Hcl	745	229
Losartan Potassium	Losartan Potassium	603	182
Lisinopril	Lisinopril	593	181
Levothyroxine Sodium	Levothyroxine Sodium	592	180
Amlodipine Besylate	Amlodipine Besylate	313	97
Omeprazole	Omeprazole	270	89
Metoprolol Succinate	Metoprolol Succinate	268	88
Gabapentin	Gabapentin	195	83
Alprazolam	Alprazolam	193	38
Pioglitazone Hcl	Pioglitazone Hcl	190	67
Tamsulosin Hcl	Tamsulosin Hcl	181	64
Alendronate Sodium	Alendronate Sodium	177	59
Tramadol Hcl	Tramadol Hcl	177	45
Pantoprazole Sodium	Pantoprazole Sodium	166	58
Simvastatin	Simvastatin	157	44
Hydrochlorothiazide	Hydrochlorothiazide	146	44
Rosuvastatin Calcium	Rosuvastatin Calcium	142	50
Carvedilol	Carvedilol	131	44
Clonazepam	Clonazepam	126	26
Meloxicam	Meloxicam	126	71
Escitalopram Oxalate	Escitalopram Oxalate	114	45
Montelukast Sodium	Montelukast Sodium	102	36
Finasteride	Finasteride	100	31
Pravastatin Sodium	Pravastatin Sodium	98	25
Januvia	Sitagliptin Phosphate	93	29
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	92	23
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	92	36
Famotidine	Famotidine	88	25
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	82	25
Clopidogrel	Clopidogrel Bisulfate	76	32
Eliquis	Apixaban	70	19
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	69	21
Furosemide	Furosemide	68	32
Donepezil Hcl	Donepezil Hcl	67	20
Duloxetine Hcl	Duloxetine Hcl	66	23
Fluticasone Propionate	Fluticasone Propionate	65	26
Pregabalin	Pregabalin	61	13
Metoprolol Tartrate	Metoprolol Tartrate	60	18
Ezetimibe	Ezetimibe	59	23
Trazodone Hcl	Trazodone Hcl	54	20
Jardiance	Empagliflozin	52	22
Memantine Hcl	Memantine Hcl	51	17
Acetaminophen-Codeine	Acetaminophen With Codeine	49	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	48	22
Doxazosin Mesylate	Doxazosin Mesylate	47	14
Fenofibrate	Fenofibrate	46	12
Sertraline Hcl	Sertraline Hcl	43	16
Glipizide	Glipizide	42	14
Mirtazapine	Mirtazapine	42	19
Nifedipine Er	Nifedipine	41	14
Glimepiride	Glimepiride	40	16
Quetiapine Fumarate	Quetiapine Fumarate	40	11
Celecoxib	Celecoxib	36	18
Citalopram Hbr	Citalopram Hydrobromide	34	suppressed
Vitamin D2	Ergocalciferol (Vitamin D2)	34	12
Farxiga	Dapagliflozin Propanediol	33	12
Oxybutynin Chloride	Oxybutynin Chloride	33	14
Diclofenac Sodium	Diclofenac Sodium	32	16
Hydralazine Hcl	Hydralazine Hcl	30	15
Olmesartan Medoxomil	Olmesartan Medoxomil	30	11
Synthroid	Levothyroxine Sodium	30	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	28	12
Naproxen	Naproxen	26	15
Misoprostol	Misoprostol	25	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	24	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	23	suppressed
Paroxetine Hcl	Paroxetine Hcl	23	13
Venlafaxine Hcl	Venlafaxine Hcl	23	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	23	suppressed
Glipizide Er	Glipizide	22	suppressed
Glipizide-Metformin	Glipizide/Metformin Hcl	22	suppressed
Omega-3 Acid Ethyl Esters	Omega-3 Acid Ethyl Esters	20	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	19	suppressed
Ibuprofen	Ibuprofen	19	13
Lyrica	Pregabalin	19	suppressed
Spironolactone	Spironolactone	19	suppressed
Benazepril Hcl	Benazepril Hcl	18	suppressed
Fentanyl	Fentanyl	18	suppressed
Ozempic	Semaglutide	18	suppressed
Telmisartan	Telmisartan	18	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	18	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	18	suppressed
Allopurinol	Allopurinol	17	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	17	suppressed
Terazosin Hcl	Terazosin Hcl	17	suppressed
Valsartan	Valsartan	17	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	16	suppressed
Prednisone	Prednisone	16	11
Symbicort	Budesonide/Formoterol Fumarate	16	suppressed
Tizanidine Hcl	Tizanidine Hcl	16	suppressed
Toujeo Solostar	Insulin Glargine,hum.Rec.Anlog	16	suppressed
Azelastine Hcl	Azelastine Hcl	15	suppressed
Baclofen	Baclofen	15	suppressed
Lactulose	Lactulose	15	suppressed
Linzess	Linaclotide	15	suppressed
Enalapril Maleate	Enalapril Maleate	14	suppressed
Levemir Flexpen	Insulin Detemir	14	suppressed
Olmesartan-Hydrochlorothiazide	Olmesartan/Hydrochlorothiazide	14	suppressed
Solifenacin Succinate	Solifenacin Succinate	14	suppressed
Tramadol Hcl-Acetaminophen	Tramadol Hcl/Acetaminophen	14	suppressed
Trulicity	Dulaglutide	14	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	13	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	13	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	13	suppressed
Temazepam	Temazepam	13	suppressed
Candesartan Cilexetil	Candesartan Cilexetil	12	suppressed
Carbamazepine	Carbamazepine	12	suppressed
Eszopiclone	Eszopiclone	12	suppressed
Levofloxacin	Levofloxacin	12	suppressed
Lorazepam	Lorazepam	12	suppressed
Procto-Med Hc	Hydrocortisone	12	suppressed
Rybelsus	Semaglutide	12	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	12	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	12	suppressed
Atenolol	Atenolol	11	suppressed
Droplet Pen Needle	Pen Needle, Diabetic	11	suppressed
Insulin Lispro Kwikpen U-100	Insulin Lispro	11	suppressed
Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	11	suppressed
Isosorbide Dinitrate	Isosorbide Dinitrate	11	suppressed
Phenobarbital	Phenobarbital	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error